Multiply Recurrent Trichilemmal Carcinoma With Perineural Invasion and Cytokeratin 17 Positivity

Allee, Julie E.; Cotsarelis, George; Solky, Benjamin A.; Cook, Jonathan L.

doi:10.1097/00042728-200308000-00028

Cited by 4 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the expression of K17 in BCC has been noted in other studies . The presence of K17 has also been noted in other tumors of proposed follicular differentiation, such as trichilemmal carcinoma, trichoblastoma, and trichoepithelioma …”

supporting

confidence: 63%

Diagnostic Utility of Cytokeratin 17 Immunostaining in Morpheaform Basal Cell Carcinoma and for Facilitating the Detection of Tumor Cells at the Surgical Margins

Anderson-Dockter

Clark

Iwamoto

et al. 2012

Dermatologic Surgery

View full text Add to dashboard Cite

Background The morpheaform subtype of basal cell carcinoma (BCC) often presents a diagnostic histological challenge, and its true margin may be difficult to determine with accuracy. This tumor may also be difficult to distinguish from other adnexal neoplasms having a benign clinical course. Previous work has shown that cytokeratin 17 (K17) expression is increased in BCC. Objective To confirm the expression of K17 across the subtypes of superficial, nodular and morpheaform BCC variants. Secondly, compare K17 expression in each of these subtypes of BCC to two other adnexal neoplasms. Methods Tissue specimens from each tumor category were randomly collected, immunolabeled, and scored for K17 expression by intensity and extent of immunostaining. Results Our results indicate that K17 is a very useful marker in the identification and outlining of BCC. Moreover, in morpheaform BCC, K17 immunostaining clearly detected individual tumor cells well away from the dermal tumor strands that otherwise seemed non-malignant by hematoxylin and eosin staining alone. In addition, we report that the expression of K17 in morpheaform BCC is capable (100% of specimens; p<0.0001) of distinguishing this tumor from desmoplastic trichoepithelioma. Conclusion We propose that K17 immunostaining could improve the diagnostic and surgical management of these tumors.

show abstract

supporting

confidence: 63%

Diagnostic Utility of Cytokeratin 17 Immunostaining in Morpheaform Basal Cell Carcinoma and for Facilitating the Detection of Tumor Cells at the Surgical Margins

Anderson-Dockter

Clark

Iwamoto

et al. 2012

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

“…In the present study, we found that: (i) tricholemmal carcinoma definitely exists and that one type of tricholemmal carcinoma seems to be related to follicular (infundibular) SCC; and (ii) the immunohistochemical profile of the normal ORS cells was generally retained in these tricholemmal carcinomas, except for CD34. Some clinically aggressive examples of possible tricholemmal carcinoma have been reported, 10,14 in spite of the general view that tricholemmal carcinomas show an indolent clinical behaviour 11 . Therefore, continued efforts to ensure the correct diagnosis of tricholemmal carcinoma will be important to determine the exact clinicopathological characteristics of this disease.…”

Section: Discussionmentioning

confidence: 99%

“…The reappraisal of tricholemmal carcinoma through considering its relationship to follicular (infundibular) SCC may help to resolve the controversy about ‘tricholemmal carcinoma’. This controversy is based on the fact that no universally accepted histopathological diagnostic criteria have yet been established for tricholemmal carcinoma 3–14 . Indeed, even the existence of tricholemmal carcinoma has been called into question by one of the present authors (NM), together with Ackerman 8 .…”

Section: Introductionmentioning

confidence: 90%

Folliculocentric squamous cell carcinoma with tricholemmal differentiation: a reappraisal of tricholemmal carcinoma

Misago¹,

Toda

Narisawa³

2012

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Some clinically aggressive examples of possible TC have, however, been reported. Allee et al 16 and Kulahci et al 17 reported cases of multiple tumour recurrence while Knoeller et al noted a case of lymphatic and skeletal metastasis 18. While these cases may well represent atypically aggressive cases of TC, it again raises questions over histopathological diagnostic accuracy.…”

Section: Discussionmentioning

confidence: 99%

Trichilemmal carcinoma: an unusual presentation of a rare cutaneous lesion

et al. 2013

View full text Add to dashboard Cite

SUMMARYTrichilemmal carcinoma (TC) is a rare cutaneous neoplasm which is derived from adnexal keratinocytes, is histologically invasive, contains cytologically atypical clear cell neoplasm and is in continuity with the epidermis and/or follicular epithelium. However, the diagnostic criteria and even the existence of TC have been contentious. We report the case of a 92-year-old woman with TC of the head and neck region who presented with an unusually long history. She was treated successfully with wide local excision. Important aspects in presentation, differential diagnosis, including histopathological features and management are discussed. BACKGROUND

show abstract

Multiply Recurrent Trichilemmal Carcinoma With Perineural Invasion and Cytokeratin 17 Positivity

Cited by 4 publications

References 19 publications

Diagnostic Utility of Cytokeratin 17 Immunostaining in Morpheaform Basal Cell Carcinoma and for Facilitating the Detection of Tumor Cells at the Surgical Margins

Diagnostic Utility of Cytokeratin 17 Immunostaining in Morpheaform Basal Cell Carcinoma and for Facilitating the Detection of Tumor Cells at the Surgical Margins

Folliculocentric squamous cell carcinoma with tricholemmal differentiation: a reappraisal of tricholemmal carcinoma

Trichilemmal carcinoma: an unusual presentation of a rare cutaneous lesion

Contact Info

Product

Resources

About